Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446996 | 0.78 | ALDH1A1 (0.53) | ACLYALDH1A1CYP2D6TSHRCYP2C19 | |
| SCHEMBL2047722 | 0.78 | LMNA (0.40) | ALDH1A1CYP2D6TSHRFFAR1TDP1 | |
| SCHEMBL5792177 | 0.76 | MEN1 (0.38) | ACLYALDH1A1TSHR | |
| SCHEMBL11048886 | 0.75 | ALDH1A1 (0.40) | ACLYALDH1A1CYP2D6TSHRCYP2C19 | |
| SCHEMBL28928933 | 0.73 | ALDH1A1 (0.64) | ACLYALDH1A1CYP2D6TSHRCYP2C19 | |
| SCHEMBL6259575 | 0.72 | ACLY (0.33) | ACLYALDH1A1TSHRKDM4ETDP1 | |
| SCHEMBL1195706 | 0.72 | ACLY (0.39) | ACLYALDH1A1CYP2D6TSHRCYP2C19 | |
| SCHEMBL185832 | 0.72 | — | — | |
| SCHEMBL9747466 | 0.70 | ALDH1A1 (0.46) | ACLYALDH1A1CYP2D6TSHRCYP2C19 | |
| SCHEMBL13044552 | 0.70 | ALDH1A1 (0.46) | ACLYALDH1A1CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053493-A1 | METHOD FOR PRODUCING FLUORINATED COPOLYMER COMPOSITION, COATING COMPOSITION, ARTICLE HAVING COATING FILM, AND MOLDED PRODUCT | ASAHI GLASS COMPANY, LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130017334-A1 | COATING COMPOSITION AND PROCESS FOR ITS PRODUCTION, AND PROCESS FOR FORMING COATING FILM BY USING THE COMPOSITION | ASAHI GLASS COMPANY, LIMITED (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | ALOX5, GSTO1, FASN | ACLY 1210/4885ALDH1A1 40/4885CYP2D6 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.